Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Purpose of reviewMetastatic pheochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumors with variable prognosis. This review highlights recent studies on outcomes and management of patients with metastatic PPGL.Recent findingsLatest advances were made in identifying predictors of favorable outcomes of patients with metastatic PPGL. Recent studies evaluated the efficacy of tyrosine kinase inhibitors, high-specific-activity radiopharmaceuticals, and peptide receptors radionuclide therapy in treatment of metastatic disease. Moreover, ongoing studies are assessing the effects of hypoxia-inducible factor 2αα and heat shock protein 90 inhibitors as potential therapies.SummarySeveral active studies are evaluating the efficacy of systemic chemo, immuno, radiopharmaceutical, and peptide receptor radionuclide therapies to relieve local and adrenergic symptoms and provide survival benefit for patients with symptomatic and/or progressive advanced metastatic PPGL. Owing to rarity and wide-outcome variability, multidisciplinary team effort and personalized approach are central in caring for patients with metastatic PPGL.

Original languageEnglish (US)
Pages (from-to)146-154
Number of pages9
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
Volume26
Issue number3
DOIs
StatePublished - Jun 1 2019

Fingerprint

Paraganglioma
Pheochromocytoma
Peptide Receptors
Radiopharmaceuticals
Radioisotopes
HSP90 Heat-Shock Proteins
Neuroendocrine Tumors
Therapeutics
Adrenergic Agents
Protein-Tyrosine Kinases
Outcome Assessment (Health Care)
Survival

Keywords

  • catecholamine-related symptoms
  • local control
  • peptide receptor radionuclide therapy
  • radiopharmaceutical therapy
  • survival outcomes
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Nutrition and Dietetics

Cite this

Metastatic pheochromocytoma and paraganglioma : recent advances in prognosis and management. / Hamidi, Oksana.

In: Current Opinion in Endocrinology, Diabetes and Obesity, Vol. 26, No. 3, 01.06.2019, p. 146-154.

Research output: Contribution to journalReview article

@article{dc335973038c4475a7335918dd0019fb,
title = "Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management",
abstract = "Purpose of reviewMetastatic pheochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumors with variable prognosis. This review highlights recent studies on outcomes and management of patients with metastatic PPGL.Recent findingsLatest advances were made in identifying predictors of favorable outcomes of patients with metastatic PPGL. Recent studies evaluated the efficacy of tyrosine kinase inhibitors, high-specific-activity radiopharmaceuticals, and peptide receptors radionuclide therapy in treatment of metastatic disease. Moreover, ongoing studies are assessing the effects of hypoxia-inducible factor 2αα and heat shock protein 90 inhibitors as potential therapies.SummarySeveral active studies are evaluating the efficacy of systemic chemo, immuno, radiopharmaceutical, and peptide receptor radionuclide therapies to relieve local and adrenergic symptoms and provide survival benefit for patients with symptomatic and/or progressive advanced metastatic PPGL. Owing to rarity and wide-outcome variability, multidisciplinary team effort and personalized approach are central in caring for patients with metastatic PPGL.",
keywords = "catecholamine-related symptoms, local control, peptide receptor radionuclide therapy, radiopharmaceutical therapy, survival outcomes, tyrosine kinase inhibitor",
author = "Oksana Hamidi",
year = "2019",
month = "6",
day = "1",
doi = "10.1097/MED.0000000000000476",
language = "English (US)",
volume = "26",
pages = "146--154",
journal = "Current Opinion in Endocrinology, Diabetes and Obesity",
issn = "1752-296X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Metastatic pheochromocytoma and paraganglioma

T2 - recent advances in prognosis and management

AU - Hamidi, Oksana

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Purpose of reviewMetastatic pheochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumors with variable prognosis. This review highlights recent studies on outcomes and management of patients with metastatic PPGL.Recent findingsLatest advances were made in identifying predictors of favorable outcomes of patients with metastatic PPGL. Recent studies evaluated the efficacy of tyrosine kinase inhibitors, high-specific-activity radiopharmaceuticals, and peptide receptors radionuclide therapy in treatment of metastatic disease. Moreover, ongoing studies are assessing the effects of hypoxia-inducible factor 2αα and heat shock protein 90 inhibitors as potential therapies.SummarySeveral active studies are evaluating the efficacy of systemic chemo, immuno, radiopharmaceutical, and peptide receptor radionuclide therapies to relieve local and adrenergic symptoms and provide survival benefit for patients with symptomatic and/or progressive advanced metastatic PPGL. Owing to rarity and wide-outcome variability, multidisciplinary team effort and personalized approach are central in caring for patients with metastatic PPGL.

AB - Purpose of reviewMetastatic pheochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumors with variable prognosis. This review highlights recent studies on outcomes and management of patients with metastatic PPGL.Recent findingsLatest advances were made in identifying predictors of favorable outcomes of patients with metastatic PPGL. Recent studies evaluated the efficacy of tyrosine kinase inhibitors, high-specific-activity radiopharmaceuticals, and peptide receptors radionuclide therapy in treatment of metastatic disease. Moreover, ongoing studies are assessing the effects of hypoxia-inducible factor 2αα and heat shock protein 90 inhibitors as potential therapies.SummarySeveral active studies are evaluating the efficacy of systemic chemo, immuno, radiopharmaceutical, and peptide receptor radionuclide therapies to relieve local and adrenergic symptoms and provide survival benefit for patients with symptomatic and/or progressive advanced metastatic PPGL. Owing to rarity and wide-outcome variability, multidisciplinary team effort and personalized approach are central in caring for patients with metastatic PPGL.

KW - catecholamine-related symptoms

KW - local control

KW - peptide receptor radionuclide therapy

KW - radiopharmaceutical therapy

KW - survival outcomes

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85065511425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065511425&partnerID=8YFLogxK

U2 - 10.1097/MED.0000000000000476

DO - 10.1097/MED.0000000000000476

M3 - Review article

C2 - 30893083

AN - SCOPUS:85065511425

VL - 26

SP - 146

EP - 154

JO - Current Opinion in Endocrinology, Diabetes and Obesity

JF - Current Opinion in Endocrinology, Diabetes and Obesity

SN - 1752-296X

IS - 3

ER -